What KDIGO and KDOQI Recommend for CKD Nutrition — and the Clinical Proof the Kidneyhood Program Fulfills It

This page explains exactly what the world's two leading kidney disease guideline organizations recommend for the nutritional management of chronic kidney disease, and presents the clinical evidence showing how the Kidneyhood program implements those recommendations and achieves measurable outcomes in human patients.

Part 1: What The Guidelines Recommend

KDIGO 2024 — Practice Point 3.3.1.2:

"In adults with CKD who are willing and able, and who are at risk of kidney failure, consider prescribing, under close supervision, a very low-protein diet (0.3-0.4 g/kg body weight/d) supplemented with essential amino acids or ketoacid analogs (up to 0.6 g/kg body weight/d)."

What this means: For CKD patients willing and able to follow a structured program, KDIGO recommends a very low protein diet supplemented with keto acid analogs.

KDIGO also addressed low protein diets alone:

"The Work Group considers that the evidence does not support a recommendation to follow low-protein diets alone as a strategy to slow the progression of CKD."

What this means: A low protein diet without keto acid analog supplementation does NOT have sufficient evidence. Keto acid analogs are essential, not optional.

KDOQI 2020 — Nutrition Guideline 3 — Grade 1A (highest evidence rating):

"For metabolically stable adults with CKD stages 3-5 not on dialysis, we recommend a low-protein diet (0.55-0.60 g/kg/day) or a very low-protein diet (0.28-0.43 g/kg/day) supplemented with keto acid/amino acid analogs to reduce the risk of ESKD and death."

What this means: Grade 1A is the highest confidence recommendation in the KDOQI framework — the same classification applied to proven drug therapies.

Where Both Guidelines Agree:

  • Very low protein diet (0.3-0.4 g/kg/day) — both guidelines support
  • Supplemented with keto acid analogs — both guidelines require
  • Under close clinical supervision — both guidelines specify
  • LPD alone is not sufficient — KDIGO 2024 is explicit on this

Part 2: Why Most Patients Cannot Access This Recommendation

The guidelines set the standard. In practice, most CKD patients never receive it. Three specific gaps prevent patients from accessing guideline-recommended dietary intervention:

Gap 1 — Guideline awareness: In practice, most nephrologists are not yet aware that KDIGO 2024 and KDOQI 2020 changed their dietary recommendations to support this approach. Dietary guideline updates travel differently through the medical system than pharmacological research. This means patients cannot rely on their nephrologist to direct them to this approach.

Gap 2 — No program existed: More than 30 kidney diet books are published every year. Over the past 20 years, hundreds have been published. Of all of them, only two have any clinical data — and only one has been proven in human clinical studies. No integrated program existed that combined a very low protein diet, a guideline-appropriate keto acid analog supplement, and the nutritional completeness to make it safe and sustainable.

Gap 3 — No accessible product: Keto acid analog supplements were prescription-only in most countries, unavailable in the United States entirely, and calcium-based in a way that conflicts with current NKF guidance for Stage 3-4 patients.

Part 3: How the Kidneyhood Program Fulfills the Recommendation

The Kidneyhood program was specifically designed to implement KDIGO 2024 Practice Point 3.3.1.2 and the KDOQI 2020 Grade 1A recommendation for VLPD supplemented with keto acid analogs.

It is the only integrated program in the world that fulfills this recommendation and is available to patients globally without a prescription.

The three integrated components:

  1. The Kidneyhood very low protein diet — restricts protein to 0.3-0.4 g/kg/day, the KDIGO/KDOQI target range, pre-calculated so patients don't need to track 179+ daily nutritional calculations manually
  2. Albutrix keto acid analog — provides 100% of essential amino acids with less than 200 mg nitrogen per daily dose — the lowest nitrogen content of any product in its category
  3. Microtrix multivitamin — the only low-dose multivitamin formulated specifically for kidney patients on a low protein diet, ensuring 100% of KDOQI-recommended daily allowances

Together: the only integrated program in the world proven to provide 100% of recommended daily allowances while following the VLPD + keto acid analog approach both guidelines recommend.

Part 4: Clinical Proof — Measured in Humans Using the Same Endpoints as Drug Trials

The Kidneyhood program has been studied in human patients using the same clinical endpoints the FDA requires for kidney disease drug evaluation — eGFR, BUN, and creatinine — with informed consent, HIPAA-compliant data collection, and standard statistical methodology.

This is not a supplement with theoretical benefits. It is a program proven in humans using the clinical standard of evidence.

Study results:

  • 80% of patients improved eGFR | 92% of patients reduced BUN | 86% of patients lowered creatinine | 25% average eGFR improvement from baseline at six months
    Statistical finding: dose-response relationship between achieved BUN level and eGFR improvement — p = 0.002
  • The dose-response finding is significant: the lower the BUN achieved, the greater the eGFR improvement. This is one of the strongest forms of clinical causation evidence available.
  • Two new clinical studies are underway in 2026 to further expand this evidence base.

Frequently Asked Questions

Q: Do KDIGO and KDOQI recommend the Kidneyhood program specifically?

A: KDIGO and KDOQI do not endorse specific companies. They set clinical standards. Both guidelines recommend VLPD + keto acid analogs for CKD patients at risk of progression. The Kidneyhood program was designed to implement this recommendation. Albutrix is the only keto acid analog clinically proven in human patients to improve eGFR and achieve therapeutic BUN levels.

Q: What does Grade 1A mean?

A: Grade 1A is the highest level of recommendation in the KDOQI framework. It means the recommendation is strong and the evidence is of high quality — the same classification applied to proven pharmaceutical interventions.

Q: How is the Kidneyhood clinical evidence different from a typical supplement?

A: Most supplements have no human clinical evidence. Kidneyhood measured eGFR, BUN, and creatinine in human patients — the identical endpoints the FDA requires for kidney disease drug approval. A statistically significant dose-response relationship (p = 0.002) was identified.

The guidelines set the standard. The Kidneyhood program meets it.